Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Tuberculosis: early-phase trial registry
2 of 30 indexed Tuberculosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 2 currently recruiting · #519 of 28,707 conditions by registered trial count
Tuberculosis: 30 US clinical trials tracked, 2 recruiting.
Tuberculosis is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 13 of these trials.
Enrollment posture brief
Registry condition tuberculosis
OPEN 2 | RECR 7% | LATE 1 | EARLY 13 | RANK #519 | SPON 13
Volume-matched condition peers
Nearest open-share peer: Liver Disease (7% recruiting · 15 trials)
Tuberculosis lists 2 open slots (7% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Tuberculosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Tuberculosis is recruiting below its size-band peers.
2 of 30 indexed trials (6.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Tuberculosis research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 13 of 30 trials (43.3%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Tuberculosis enrolment sits around 135 participants.
Median target enrolment is 135 among the 30 trials that report a genuine target (sentinel values excluded). 14 of those (46.7%) plan for fewer than 100 participants.
-
Tuberculosis splits between interventional and observational designs.
17 interventional and 13 observational studies make up this index (56.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
Training Protocol on the Natural History of Tuberculosis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01212003
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04052022
PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04926922
Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis
Centers for Disease Control and Prevention
NCT01622140
A Registry of Tuberculosis Cases in the CPCRA
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000785
Nutrition, Immunology and Epidemiology of Tuberculosis
Harvard School of Public Health (HSPH)
NCT00197704
TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment
Centers for Disease Control and Prevention
NCT00144417
Evaluation of the QuantiFERON-TB Test.
QIAGEN Gaithersburg
NCT02256839
Effectiveness of Public Health Model of Latent Tuberculosis Infection Control for High-Risk Adolescents
San Diego State University
NCT00233168
TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen
Centers for Disease Control and Prevention
NCT00023361
Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02534727
Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04518228
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
University of Virginia
NCT05283967
Behavioral Interventions for Control of TB
Columbia University
NCT00005739
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis (TB) in Elderly Residents of Nursing Homes?
Northwell Health
NCT00756808
Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NCT03819114
TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance
Centers for Disease Control and Prevention
NCT00023374
Gene Expression in HIV and Tuberculosis Co-infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01611402
Challenge Model for Assessment of Human TB Immunity
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01868464
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00396084
Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers
Sequella
NCT01585636
Phase I Trial of DAR-901
Dartmouth-Hitchcock Medical Center
NCT02063555
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
Global Alliance for TB Drug Development
NCT02288481
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000778
Expression of Tuberculosis in the Lung
University of Medicine and Dentistry of New Jersey
NCT00201253
Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00992069
A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
Global Alliance for TB Drug Development
NCT05526911
Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects
Global Alliance for TB Drug Development
NCT04865536
A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03891901
Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03896750
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Tuberculosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Tuberculosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Tuberculosis page
30 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Tuberculosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most Tuberculosis trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Tuberculosis condition card totals 30 registered trials; most-linked intervention Isoniazid; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.